Live from AUA2025: Advances in ADT (2025)

Overview

Live from AUA2025: Advances in ADT will discuss the best in the latest advancements in androgen deprivation therapy (ADT) from the AUA Annual Meeting!

This activity is designed to increase the urologist’s understanding of how to translate the latest clinical guidelines and scientific advances related to ADT into their routine clinical practice, improving the care of patients with advanced prostate cancer.  This activity will highlight content presented at the AUA2025 focused on ADT, including the latest AUA and NCCN Guidelines, different modalities of ADT and future directors of ongoing research. 

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

  • Pfizer, Inc. 
  • Sumitomo Pharma America, Inc. 

Target Audience

  • Urologists
  • Urologists in training
  • Non-physician providers involved in urology

Learning Objectives

At the conclusion of this CME activity, participants will be able to:

  1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice
  2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings.
  3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT.
  4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes.
  5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT.
  6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
04/29/2025
Course expires: 
04/29/2026
Rating: 
0

Faculty

Education Council Disclosures

PDF icon Education Council Disclosures.pdf

COI Work Group Disclosures

PDF icon COI Review Workgroup Disclosures.pdf

Faculty Disclosures

NameCompany NameRelationship TypeEnd Date
Barata, PedroAstellasConsultant or AdvisorCurrent
Barata, PedroAstraZenecaConsultant or AdvisorCurrent
Barata, PedroBayerConsultant or AdvisorCurrent
Barata, PedroCaris Life SciencesConsultant or AdvisorCurrent
Barata, PedroEisaiMeeting Participant or LecturerCurrent
Barata, PedroEMD SeronoConsultant or Advisor12/01/2023
Barata, PedroExelixisConsultant or AdvisorCurrent
Barata, PedroIpsenConsultant or AdvisorCurrent
Barata, PedroNateraConsultant or Advisor12/01/2023
Barata, PedroNovartisConsultant or AdvisorCurrent
Barata, PedroPfizerConsultant or AdvisorCurrent
Barata, PedroSeattle GeneticsScientific Study or TrialCurrent
Cookson, Michael S.BayerConsultant or Advisor12/31/2026
Cookson, Michael S.Janssen Scientific AffairsConsultant or Advisor12/30/2023
Cookson, Michael S.Johnson & JohnsonConsultant or Advisor12/10/2024
Cookson, Michael S.MDxHealthScientific Study or Trial09/01/2025
Cookson, Michael S.Nonagen Bioscience Corp.Consultant or Advisor07/11/2023
Cookson, Michael S.PfizerConsultant or AdvisorCurrent
Cookson, Michael S.Progenics Phamaceuticals, Inc. (Lanthues)Consultant or Advisor08/01/2023
Cookson, Michael S.ProkariumConsultant or Advisor11/30/2024
Cookson, Michael S.PropellaConsultant or Advisor11/04/2023
Hastings, RachelNothing relevant to disclose  
Morris, David ScottAstellasConsultant or AdvisorCurrent
Morris, David ScottAstraZenecaConsultant or AdvisorCurrent
Morris, David ScottBayerConsultant or AdvisorCurrent
Morris, David ScottBlue Earth DiagnosticsConsultant or AdvisorCurrent
Morris, David ScottCleveland DiagnosticsConsultant or AdvisorCurrent
Morris, David ScottDecipher BioConsultant or AdvisorCurrent
Morris, David ScottDendreonConsultant or AdvisorCurrent
Morris, David ScottJanssenConsultant or AdvisorCurrent
Morris, David ScottLantheusConsultant or AdvisorCurrent
Morris, David ScottMerckConsultant or AdvisorCurrent
Morris, David ScottMyovantConsultant or AdvisorCurrent
Morris, David ScottMyriadConsultant or AdvisorCurrent
Morris, David ScottPfizerMeeting Participant or LecturerCurrent
Morris, David ScottTolmarConsultant or AdvisorCurrent
Morris, David ScottUroGen PharmaConsultant or AdvisorCurrent
Scarpato, Kristen R.Nothing relevant to disclose  

AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.


 

Accreditation

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: April, 2025
Expiration Date: April, 2026

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation

Register/Take course

Please login or register to take this course.